Drug Profile
Research programme: protein tyrosine phosphatase beta inhibitors - Akebia
Alternative Names: HPTPβ inhibitors - AkebiaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer Akebia Therapeutics
- Class Small molecules
- Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Vascular disorders
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in USA
- 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Vascular disorders presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
- 07 Jan 2010 Protein tyrosine phosphatase beta inhibitors are available for licensing (http://www.akebia.com)